Format

Send to

Choose Destination
J Hypertens. 2018 Oct;36(10):2042-2048. doi: 10.1097/HJH.0000000000001858.

European Society of Hypertension position paper on renal denervation 2018.

Author information

1
University Hospital Erlangen, Department of Nephrology and Hypertension, Erlangen.
2
Department of Internal Medicine, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany.
3
Paris-Descartes University.
4
Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Hypertension Unit, Paris.
5
Clinique Pasteur, Hypertension, Risk Factors and Heart Failure Unit, Clinical Research Center, Toulouse, France.
6
Hippokration General Hospital, Hypertension Unit, Athens, Greece.
7
Maastricht University Medical Center (Department of Internal Medicine) and Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands.
8
Paracelsus Medical University, Department of Nephrology and Hypertension, Nürnberg, Germany.
9
Policlinico di Monza, Interventional Cardiology, Monza.
10
University of Milano-Bicocca, Milan, Italy.
11
National and Kapodistrian University of Athens, 1st Cardiology Clinic, Hippocratio Hospital, Athens, Greece.

Abstract

: This ESH update was deemed necessary with the publication of new results of sham-controlled randomized blinded prospective trials with renal denervation (RDN). Proof of concept studies and first randomized trials (some were sham-controlled) displayed discrepant results about the efficacy of RDN. Three sham-controlled randomized trials of the 2.0 generation yielded now similarity in the average blood pressure decrease following RDN. Reduction of ambulatory blood pressure was approximately 5 to 7 mmHg and of office blood pressure 10 mmHg. Such a decrease in blood pressure by pharmacologic therapy has been found to be associated with lower incidence of cardiovascular events in particular with respect to heart failure and stroke by roughly 25%. Nevertheless, some questions about renal denervation are unanswered. The heterogeneity of the blood pressure-lowering response point to the clinical need to identify predictors for efficacy, and questions on long-term safety could not have been answered due to the short duration of the sham-controlled randomized clinical trials.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center